Peptide Research Explainedhttps://bsky.app/profile/peptidings.bsky.socialhttps://bsky.app/profile/peptidings.bsky.social/post/3mkeckaqofh2c"We're about to find out whether the 2023 ban was a reasonable mistake or the first of several." I'd bet on the first read. The system corrects more often than it doesn't. Docket open through July 22. https://peptidings.substack.com/p/seven-peptides-two-days-a-decade26 Apr 2026 00:32 +0000at://did:plc:dousy22jqwy3ujniej2cssub/app.bsky.feed.post/3mkeckaqofh2chttps://bsky.app/profile/peptidings.bsky.social/post/3mke3to4nat2sThe thing nobody is reporting about July 23–24: 503A pharmacies are already hiring peptide chemists. Already buying LC-MS/MS equipment. Already drafting monographs. They're positioning for the outcome. https://peptidings.substack.com/p/seven-peptides-two-days-a-decade25 Apr 2026 22:32 +0000at://did:plc:dousy22jqwy3ujniej2cssub/app.bsky.feed.post/3mke3to4nat2shttps://bsky.app/profile/peptidings.bsky.social/post/3mkdv53uz6o24A favorable FDA vote on the seven peptides doesn't end the research-chemical gray market. It bifurcates it. A new legal lane opens. The unregulated lane continues. Both grow. Nobody is saying this out loud. https://peptidings.substack.com/p/seven-peptides-two-days-a-decade25 Apr 2026 20:32 +0000at://did:plc:dousy22jqwy3ujniej2cssub/app.bsky.feed.post/3mkdv53uz6o24https://bsky.app/profile/peptidings.bsky.social/post/3mkdogjs6wz2iBPC-157 has more than 100 published rodent injury studies. It has almost no controlled human trial data. On July 23, the FDA's advisory committee decides whether that's enough to make it legally compoundable for ulcerative colitis. https://peptidings.com/peptides/bpc-157/25 Apr 2026 18:32 +0000at://did:plc:dousy22jqwy3ujniej2cssub/app.bsky.feed.post/3mkdogjs6wz2ihttps://bsky.app/profile/peptidings.bsky.social/post/3mkdgarktcz2g"The most regulated channel got restricted. The least regulated channel stayed wide open." What the 2023 peptide ban did, and why July's FDA review matters more than the headlines say. The Behind the Evidence column is up: https://peptidings.substack.com/p/seven-peptides-two-days-a-decade25 Apr 2026 16:05 +0000at://did:plc:dousy22jqwy3ujniej2cssub/app.bsky.feed.post/3mkdgarktcz2ghttps://bsky.app/profile/peptidings.bsky.social/post/3mkblmtkl2p2s90 seconds after the Federal Register notice hit on April 16, I thought I'd misread it. Seven peptides—BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, Epitalon—scheduled for public review at FDA on July 23–24. The biggest regulatory moment for peptides since 2023. 🧵24 Apr 2026 22:36 +0000at://did:plc:dousy22jqwy3ujniej2cssub/app.bsky.feed.post/3mkblmtkl2p2shttps://bsky.app/profile/peptidings.bsky.social/post/3mk4gsotbgh2cThe FDA is removing 12 peptides from Category 2 of the 503A bulks list this week—April 22 effective date per Orrick's legal analysis. This is not a Category 1 decision. This is not approval. The substances are in regulatory limbo until PCAC acts. Headlines will get this wrong. Do not let them.22 Apr 2026 21:27 +0000at://did:plc:dousy22jqwy3ujniej2cssub/app.bsky.feed.post/3mk4gsotbgh2c